Three‐year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post‐marketing surveillance study
2018 ◽
Vol 11
(2)
◽
pp. O152-O161
◽
Keyword(s):
2017 ◽
Vol 11
(1)
◽
pp. 14-23
◽
Keyword(s):
2016 ◽
Vol 32
(8)
◽
pp. 1361-1366
Keyword(s):
Keyword(s):
Keyword(s):
2018 ◽
Vol 83
(1)
◽
pp. 201-207
◽